Monday, March 19, 2007

High blood pressure? Check your neck.

Chiropractic Cuts Blood Pressure

Study Finds Special 'Atlas Adjustment' Lowers Blood Pressure
By Daniel J. DeNoon
WebMD Medical News
Reviewed by Louise Chang, MD

March 16, 2007 -- A special chiropractic adjustment can significantly lower high blood pressure, a placebo-controlled study suggests.

"This procedure has the effect of not one, but two blood-pressure medications given in combination," study leader George Bakris, MD, tells WebMD. "And it seems to be adverse-event free. We saw no side effects and no problems," adds Bakris, director of the University of Chicago hypertension center.

Eight weeks after undergoing the procedure, 25 patients with early-stage high blood pressure had significantly lower blood pressure than 25 similar patients who underwent a sham chiropractic adjustment. Because patients can't feel the technique, they were unable to tell which group they were in.

X-rays showed that the procedure realigned the Atlas vertebra -- the doughnut-like bone at the very top of the spine -- with the spine in the treated patients, but not in the sham-treated patients.

Compared to the sham-treated patients, those who got the real procedure saw an average 14 mm Hg greater drop in systolic blood pressure (the top number in a blood pressure count), and an average 8 mm Hg greater drop in diastolic blood pressure (the bottom blood pressure number).

None of the patients took blood pressure medicine during the eight-week study.

"When the statistician brought me the data, I actually didn't believe it. It was way too good to be true," Bakris says. "The statistician said, 'I don't even believe it.' But we checked for everything, and there it was."

Bakris and colleagues report their findings in the advance online issue of the Journal of Human Hypertension.

Saturday, March 17, 2007

Supplements for Migraines

Migraines: Much-needed relief from migraine attacks

When the big guns aren't effective, it may be time
to go back and give some simple tools a try. That's
the finding of a new study that tested dietary
supplements on patients who had been unsuccessful in
relieving migraines with a variety of drugs.


Migraines: Preliminary results look promising


Could free radical damage contribute to migraine
headaches? Dr. Sirichai Chayasirisobhon of Kaiser
Permanente Medical Center set out to address that
question when he recruited a dozen patients, each
with a long-term history of little or no success at
treating migraines with various drugs, including
antidepressants, beta-blockers and anticonvulsants.

At the outset of the study, subjects completed a
migraine disability assessment (MIDAS) questionnaire
to assess the impact of migraine flare-ups on
activities at home, at work and while interacting
with friends and family. For the three-month trial
period, each subject received daily supplements that
contained 600 mg of vitamin C, 300 IU of vitamin E
and 1,200 mg of a pine bark extract. Subjects were
allowed to continue using whatever medications they
were currently taking.

When subjects completed a second MIDAS questionnaire
at the end of the study period, their responses
indicated a marked improvement. And even though the
lack of a control group opens the possibility of
placebo effect, the results were promising:


* The overall MIDAS score improvement was more
than 50 percent


* Average Number of migraine days was reduced
from 44 days in the three months prior to
supplementation, to just 26 days during the trial
period


* Average migraine severity score was reduced
from 7.5 (out of 10) to 5.5


One subject dropped out of the trial. Of the
remaining 11, two reported no change in migraine
frequency, duration or severity. Among the other
nine, the overall MIDAS score improvement was nearly
68 percent.


Migraines: CoQ10 helps alleviate migraines


So...what's up with this pine bark extract?

Although not identified in the study, I believe the
extract is almost certainly Pycnogenol; a natural
antioxidant extracted from French maritime pine
bark. Pycnogenol contains a variety of polyphenols
with anti-inflammatory properties that have been
shown to benefit the cardiovascular system by
promoting proper blood flow. In a previous e-Alert
we compared the effectiveness of Pycnogenol's
antioxidant qualities to two of the most powerful
antioxidants: glutathione and coenzyme Q10 (CoQ10).

In fact, Dr. Chayasirisobhon might have produced

even more impressive migraine relief if he had added
CoQ10 to the supplement mix.

In a CoQ10 trial conducted in 2002, 32 migraine
patients each received 150 mg of the antioxidant
daily for three months. In the month before the
study began, the group experienced an average of
more than seven days of migraine each. But by the
end of the study that monthly average had dropped to
just under three days. About 60 percent of the
subjects reported that their frequency of migraines
dropped to less than half of what it had been before
the study.

And in another e-Alert I told you about a Swiss
study in which 42 migraine patients received either
100 mg of CoQ10 three times each day, or a placebo.
No other methods were used to prevent migraines.
After three months of supplementation, researchers
found that migraine frequency, total days with
migraine, and total days with nausea were all
significantly reduced in the CoQ10 group, compared
to placebo. Overall, the incidence of migraines was
almost cut in half in the CoQ10 group, while the
reduction of migraines in the placebo group was less
than 15 percent.

When this research was presented at the 2004 annual
meeting of the American Academy of Neurology, the
Swiss team noted that migraines might be triggered
by a breakdown in the production of cellular energy.
They theorised that CoQ10 helps prevent migraines by
promoting proper respiration in the powerhouses of
the cell: the mitochondria.

If you suffer from migraines, talk to your doctor or
a healthcare professional about these promising
antioxidant studies before expanding your supplement
regimen.

Sources:

"Use of a Pine Bark Extract and Antioxidant Vitamin
Combination Product as Therapy for Migraine in
Patients Refractory to Pharmacologic Medication"
Headache: The Journal of Head and Face Pain, Vol.
46, No. 5, May 2006, Blackwell-synergy.com
"Antioxidant Combo May Prevent Some Migraines"
Reuters Health, 6/1/06, reutershealth.com "Teen
Refuses Court-Ordered Test to Check Cancer Status"
Elizabeth Simpson, The Virginian-Pilot, 6/26/06,
home.hamptonroads.com "Judge OKs Alternative
Treatment for Teen" The Guardian, 6/2/06,
guardian.co.uk

Help for Retinoblastoma

Tree bark extract might help treat rare eye cancer

By Julie SteenhuysenFri Mar 16, 1:07 AM ET

An extract from the bark of a South American tree might lead to better treatments for a rare but deadly childhood eye cancer called retinoblastoma, U.S. researchers reported on Friday.

Retinoblastoma affects 1 in 15,000 children, causing about 3 percent of all cancers in children. It forms when developing cells in the retina -- the eye's main light sensor -- go haywire and start reproducing out of control.

"The great majority of the cases exist in the developing world, where it is a fatal disease," said Dr. Joan O'Brien of the University of California, San Francisco, who led the study.

The cancer usually develops in children under age 6 and kills within two to four years after diagnosis if not treated.

If detected early and treated with a combination of chemotherapy agents or radiation, 90 to 95 percent of children live. But conventional treatment has significant side effects.

Combination chemotherapy can cause hearing loss, kidney failure and leukemia. Radiation therapy, which is now less commonly used, disfigures the child.

In children who have the cancer in only one eye, the eyeball is sometimes replaced with an implant.

"We can cure them, but at cost," said O'Brien. "It's important to find a cheap, easily administered, nontoxic therapy."

O'Brien and colleagues at UCSF wanted to see whether the tree bark extract beta-lapachone could cause the abnormal cells to commit suicide -- something it has been shown to do in a number of cancer types, including breast and prostate cells.

They tested the extract in the laboratory and found that beta-lapachone significantly blocked rapid cell growth of human tumor cells and that low doses could cause damaged cells to kill themselves in a process called apoptosis, or programmed cell death.

Writing in the journal Eye, the scientists said their findings support other studies of the extract in different human cancers and may lead to an effective treatment.

"The nice thing about the agent is that it kills at very low doses and it appears to be selective to cancer," O'Brien said.

Substances that zero in on cancer are less toxic because they do less harm to healthy cells, O'Brien said. Her lab is now testing the extract in mice with retinoblastoma to look for possible toxic side effects.

Wednesday, March 14, 2007

5-HTP; Help for mood and sleep

5-Hydroxytryptophan (5-HTP)

Overview
Uses
Dietary Sources
Available Forms
How to Take It
Precautions
Possible Interactions
Supporting Research


Overview

5-hydroxytryptophan (5-HTP) is an amino acid. The body makes 5-HTP from tryptophan (an essential amino acid) and converts it to an important brain chemical known as serotonin. Tryptophan and 5-HTP dietary supplements help raise serotonin levels in the brain, which may have a positive effect on sleep, mood, anxiety, aggression, appetite, temperature, sexual behavior, and pain sensation.

It is important to note, however, that an outbreak of eosinophilic myalgia syndrome (EMS; a potentially fatal disorder that affects the skin, blood, muscles, and organs) caused by a contaminated batch of tryptophan led to the removal of all tryptophan supplements from the United States market in 1989. Although the manufacturing of 5-HTP is different from that of tryptophan, there is still concern that some 5-HTP supplements may contain similar contaminants. It is important to obtain dietary supplements from manufacturers that adhere to high quality standards. At least two organizations, NSF International and the United States Pharmacopeia (USP), offer programs that make sure manufacturers follow high quality practices. As a result, these manufacturers often indicate this information on their product labels.



Uses

5-HTP may be helpful in treating a wide variety of conditions related to low serotonin levels, including the following:

Depression

Low levels of serotonin in the brain can contribute to the development of depression. Many drugs prescribed for depression increase serotonin levels. Some studies indicate that 5-HTP may be as effective as certain antidepressant drugs in treating individuals with mild to moderate depression. Such individuals have shown improvements in mood, anxiety, insomnia, and physical symptoms.

Fibromyalgia

Although many factors can influence the stiffness, pain, and fatigue associated with fibromyalgia, evidence from several studies indicates that low serotonin levels may play a role in the development of this condition. 5-HTP has been shown to improve sleep quality and reduce pain, stiffness, anxiety, and depression in individuals with fibromyalgia.

Insomnia

Medical research indicates that supplementation with tryptophan before bedtime can induce sleepiness and delay wake times. Studies also suggest that 5-HTP may be useful in treating insomnia associated with depression.

Headaches

Some studies suggest that 5-HTP may be effective in children and adults with various types of headaches including migraines.

Obesity

There is some evidence that low tryptophan levels may contribute to excess fat and carbohydrate intake (which can result in weight gain). A study of overweight individuals with diabetes suggests that supplementation with 5-HTP may decrease fat and carbohydrate intake by promoting a feeling of satiety (fullness). Additional similar studies of obese men and women without diabetes found that supplementation with 5-HTP resulted in decreased food intake and weight loss.



Dietary Sources

5-HTP is not commonly available in food but the amino acid tryptophan, from which the body makes 5-HTP, can be found in turkey, chicken, milk, potatoes, pumpkin, sunflower seeds, turnip and collard greens, and seaweed.



Available Forms

5-HTP can be obtained in the diet (from the conversion of tryptophan) or in supplement form. 5-HTP supplements are made from extracts of the seeds of the African tree Griffonia simplicifolia. 5-HTP can also be found in a variety of multivitamin and herbal preparations.



How to Take It

Pediatric

There are no known scientific reports on the pediatric use of 5-HTP. Therefore, it is not currently recommended for children.

Adult

50 mg of 5-HTP taken one, two, or three times per day is generally recommended for most of the conditions discussed in the Uses section.



Precautions

Because of the potential for side effects and interactions with medications, dietary supplements should be taken only under the supervision of a knowledgeable healthcare provider.

As mentioned previously, tryptophan use has been associated with the development of serious conditions such as liver and brain toxicity, and with eosinophilic myalgia syndrome (EMS), a potentially fatal disorder that affects the skin, blood, muscles, and organs. Such reports prompted the FDA to ban the sale of all tryptophan supplements in 1989. As with tryptophan, EMS has been reported in 10 people taking 5-HTP.

5-HTP may cause mild gastrointestinal disturbances including nausea, heartburn, flatulence, feelings of fullness, and rumbling sensations in some people. Pregnant or nursing women and individuals with high blood pressure or diabetes should consult a healthcare practitioner before taking 5-HTP.

In addition, as described in the Interactions section below, 5-HTP should not be taken at the same time as antidepressants.



Possible Interactions

If you are currently being treated with any of the following medications, you should not use 5-HTP without first talking to your healthcare provider.

Antidepressant Medications

Individuals taking the antidepressant medications known as selective serotonin reuptake inhibitors (SSRIs) (such as fluoxetine, paroxetine, sertraline, and citalopram) and monoamine oxidase inhibitors (MAOIs) (such as phenelzine, isocarboxazid, selegiline, and tranylcypromine) should not use 5-HTP as these medications enhance the action of these drugs and may increase the risk for developing a dangerous condition known as "serotonin syndrome." Serotonin syndrome is characterized by mental status changes, rigidity, hot flashes, rapidly fluctuating blood pressure and heart rate, and possibly coma. Similarly, other drugs for depression that interfere with the uptake of the neurotransmitter serotonin, namely trazodone and venlafexine, may also lead to serotonin syndrome when used along with 5-HTP.

Carbidopa

Taking 5-HTP with carbidopa, a medication used to treat Parkinson's disease, has been associated with side effects including scleroderma-like illnesses (a condition in which the skin becomes hard, thick, and inflamed).

Sumatriptan
Similar to antidepressants, sumatriptan, a medication used for migraine headaches that works by stimulating serotonin receptors in the brain, should also not be used in combination with 5-HTP because of the risk for serotonin syndrome.

Tramadol

Tramadol, used for pain control, may also increase serotonin levels too much if taken in combination with 5-HTP. Serotoninsyndrome has been reported in some people taking the two together.

Zolpidem

Use of zolpidem, a medication for insomnia, can cause hallucinations when used with SSRI antidepressants. Because 5-HTP may work similarly to SSRIs, the combination of 5-HTP with zolpidem could, theoretically, lead to hallucinations as well.

Zinc Increases Immune Response

ORIGINAL RESEARCH COMMUNICATION

Zinc supplementation decreases incidence of infections in the elderly: effect of zinc on generation of cytokines and oxidative stress1,2,3

Ananda S Prasad1, Frances WJ Beck1, Bin Bao1, James T Fitzgerald1, Diane C Snell1, Joel D Steinberg1 and Lavoisier J Cardozo1

1 From the Wayne State University School of Medicine, Detroit, MI (ASP, FWJB, BB, DCS, JDS, and LJC), and the University of Michigan, Ann Arbor, MI (JTF)

Background: Zinc deficiency, cell-mediated immune dysfunction, susceptibility to infections, and increased oxidative stress have been observed in elderly subjects (ie, those >55 y old). Zinc is an effective antiinflammatory and antioxidant agent.

Objectives: The primary objective was to determine the effect of zinc on the incidence of total infections in healthy elderly subjects. The secondary objective was to determine the effect of zinc on cytokines and oxidative stress markers.

Design: A randomized, double-blind, placebo-controlled trial of zinc supplementation was conducted in elderly subjects. Fifty healthy subjects of both sexes aged 55–87 y and inclusive of all ethnic groups were recruited for this study from a senior center. The zinc-supplemented group received zinc gluconate (45 mg elemental Zn/d) orally for 12 mo. Incidence of infections during the supplementation period was documented. The generation of inflammatory cytokines, T helper 1 and T helper 2 cytokines, and oxidative stress markers and the plasma concentrations of zinc were measured at baseline and after supplementation.

Results: Compared with a group of younger adults, at baseline the older subjects had significantly lower plasma zinc, higher ex vivo generation of inflammatory cytokines and interleukin 10, and higher plasma oxidative stress markers and endothelial cell adhesion molecules. The incidence of infections and ex vivo generation of tumor necrosis factor {alpha} and plasma oxidative stress markers were significantly lower in the zinc-supplemented than in the placebo group. Plasma zinc and phytohemagglutin-induced interleukin 2 mRNA in isolated mononuclear cells were significantly higher in the zinc-supplemented than in the placebo group.

Conclusions: After zinc supplementation, the incidence of infections was significantly lower, plasma zinc was significantly higher, and generation of tumor necrosis factor {alpha} and oxidative stress markers was significantly lower in the zinc-supplemented than in the placebo group.

Key Words: Elderly subjects • infections • interleukin 2 mRNA • zinc • oxidative stress • tumor necrosis factor {alpha} • interleukin 1ß

The Cost of Untreated Insomnia

Untreated Insomnia Has Exhausting Effect on Health Resources

Caroline Cassels

Medscape Medical News 2007. © 2007 Medscape

March 8, 2007 — The costs of untreated insomnia far outweigh the costs of not treating this common disorder, which affects 10% of the US population, a new study suggests.

Investigators from Cornell University found even the most expensive medications cost less than $200 per year for the typical insomnia patient vs $924 to $1143 more in medical expenses in the 6 months before treatment initiation.

"Our study suggests that it costs far less to treat insomnia than to ignore it. Untreated insomnia affects individuals' health, quality of life,and job performance — and increases their use of healthcare services substantially," said the study's lead author, Ronald Ozminkowski, PhD, from the Institute for Health and Productivity Studies, Cornell University, Washington, DC, in a statement from the American Academy of Sleep Medicine.

The study is published in the March issue of Sleep.

Using data from self-insured, employer-sponsored health insurance plans in the United States, investigators examined health and employment data from 214,378 patients with insomnia and looked at their health costs in the 6 months before diagnosis.

Unconventional Approach

According to the authors, the typical approach used to assess the burden of insomnia has been has been to focus on the current cost of treatment. However, they note, looking at costs of untreated insomnia may be more informative.

"Unlike many other medical conditions, insomnia is not an expensive condition to treat. . . . We therefore assumed that a more complete understanding of its burden of illness can be gained by estimating cost differences between similar insomnia and noninsomnia patients, shortly before diagnosis or treatment begins," they write.

Direct costs were investigated using information from medical claims for inpatient, outpatient, pharmacy, and emergency room expenses from July 1, 1999 to June 30, 2003. Expenditures for these services were all adjusted for inflation to reflect 2003 metrics.

Expenditures for 138,820 patients aged 18 to 64 years and 75,558 elderly insomnia patients older than 64 years were compared with 2 equal-sized, matched control groups who did not have insomnia.

To estimate indirect costs, absenteeism records and short-term disability program records were examined for matched workers who did and did not develop insomnia.

Insomnia Burden Underestimated?

The investigators found that combined direct and indirect medical expenses for younger patients were $1253 higher for those eventually diagnosed with insomnia compared with controls without insomnia. Similarly, combined costs for elderly patients diagnosed with insomnia were $1,143 higher that those of their counterparts without insomnia.

With approximately 25 million to 30 million Americans suffering from chronic insomnia, the authors point out that their findings have major implications for employers, health plans, government insurance programs, and individuals.

In addition, they note, the study did not take into account the impact of insomnia on psychosocial functioning, accident rates, or productivity at work and therefore the calculations in this study may be an underestimation of the insomnia burden in the United States.

Furthermore, it is known that many insomnia patients do not seek medical treatment and therefore it is likely that a proportion of the control groups had undiagnosed or untreated insomnia, which may also lead to a conservative estimate of cost burden.

Sleep. 2007;30:263-273.

Thursday, March 8, 2007

I find this study interesting but the practical applications are still a ways off. Cluster headaches can be a huge problem. Very difficult to control.




Brain stimulation may ease headaches



Stimulating the brain with implanted electrodes appears to help ease the pain of cluster headaches, two separate teams of researchers reported on Wednesday.

In one study, six out of eight patients said they got relief from cluster headaches, blindingly painful headaches that come back again and again.

Two out of eight patients in a second study said they were headache-free for more than a year using the device, and three more reported a 90-percent drop in the frequency of attacks.

Writing in the Lancet medical journal and its sister publication Lancet Neurology, the researchers said it was important to target the correct area -- the occipital nerve.

"Occipital nerve stimulation in cluster headache seems to offer a safe, effective treatment option that could begin a new era of neurostimulation therapy for primary headache symptoms," Peter Goadsby of University College London in Britain and the University of California, San Francisco, said in a statement.

Cluster headaches are marked by periods with many attacks of extremely severe headaches. Patients often must take preventive medication every day for years. But in some cases, drugs do no good.

Researchers have tried using brain stimulation before but it targeted a region called the posterior hypothalamus. Patients risk developing a fatal hemorrhage.

Techniques that stimulate the occipital nerve have been tested on other types of headaches.

Goadsby and colleagues tested the technique on eight patients with chronic cluster headaches that defied medications. After more than a year and a half, six of the eight said they would recommend the treatment to others.

Symptoms returned almost immediately when the device's battery wore down and it stopped working, the researchers said.

In the second report, Jean Schoenen and colleagues from the Headache Research Unit of Belgium's Liege University tested eight patients separately.

Two patients had no pain after 16 months and 22 months, respectively, and three more said they had 90 percent fewer headaches.

Only one patient switched off his stimulator after four months because he said it did not work.

In a commentary, Anna Ambrosini of the Headache Clinic at Neuromed in Pozzilli, Italy, said stimulating the hypothalamus got better results, but the new approach was worth testing in a larger group of patients.